Santhera Pharmaceuticals Return On Equity vs. Net Income

SANN Stock  CHF 16.00  0.34  2.08%   
Based on Santhera Pharmaceuticals' profitability indicators, Santhera Pharmaceuticals Holding may not be well positioned to generate adequate gross income at this time. It has a very high odds of underperforming in March. Profitability indicators assess Santhera Pharmaceuticals' ability to earn profits and add value for shareholders.
 
Return On Equity  
First Reported
2010-12-31
Previous Quarter
(1.74)
Current Value
(1.83)
Quarterly Volatility
10.54512552
 
Credit Downgrade
 
Yuan Drop
 
Covid
 
Interest Hikes
Price To Sales Ratio is likely to drop to 4.39 in 2026. Days Sales Outstanding is likely to drop to 141.55 in 2026. At this time, Santhera Pharmaceuticals' Income Tax Expense is fairly stable compared to the past year. Change To Netincome is likely to climb to about 15.3 M in 2026, whereas Operating Income is likely to drop (40.3 M) in 2026. Gross Profit Margin is likely to climb to 0.74 in 2026, whereas Gross Profit is likely to drop slightly above 17.4 M in 2026.
Current ValueLast YearChange From Last Year 10 Year Trend
Gross Profit Margin0.740.53
Significantly Up
Very volatile
For Santhera Pharmaceuticals profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Santhera Pharmaceuticals to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Santhera Pharmaceuticals Holding utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Santhera Pharmaceuticals's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Santhera Pharmaceuticals Holding over time as well as its relative position and ranking within its peers.
  
Check out World Market Map.
By analyzing Santhera Pharmaceuticals' earnings estimates, investors can diagnose different trends across Santhera Pharmaceuticals' analyst sentiment over time as well as compare current EPS estimates against different timeframes. Please be aware that the consensus of earnings estimates for Santhera Pharmaceuticals Holding is based on EPS before non-recurring items and includes expenses related to employee stock options.
 
Yuan Drop
 
Covid
 
Interest Hikes
Santhera Pharmaceuticals is projected to generate -0.0125 in earnings per share on the 31st of December 2026. Santhera Pharmaceuticals earnings estimates show analyst consensus about projected Santhera Pharmaceuticals Holding EPS (Earning Per Share). It derives the highest and the lowest estimates based on Santhera Pharmaceuticals' historical volatility. Many public companies, such as Santhera Pharmaceuticals, manage the perception of their earnings on a regular basis to make sure that analyst estimates are accurate. Future earnings calculations are also an essential input when attempting to value a firm. By analyzing Santhera Pharmaceuticals' earnings estimates, investors can diagnose different trends across Santhera Pharmaceuticals' analyst sentiment over time as well as compare current estimates against different timeframes.
Please note, there is a significant difference between Santhera Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Santhera Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. Conversely, Santhera Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.

Santhera Pharmaceuticals Net Income vs. Return On Equity Fundamental Analysis

Comparative valuation techniques use various fundamental indicators to help in determining Santhera Pharmaceuticals's current stock value. Our valuation model uses many indicators to compare Santhera Pharmaceuticals value to that of its competitors to determine the firm's financial worth.
Santhera Pharmaceuticals Holding is rated below average in return on equity category among its peers. It also is rated below average in net income category among its peers . At this time, Santhera Pharmaceuticals' Return On Equity is fairly stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Santhera Pharmaceuticals' earnings, one of the primary drivers of an investment's value.

Santhera Net Income vs. Return On Equity

Return on Equity or ROE tells company stockholders how effectually their money is being utilized or reinvested. It is a useful ratio when analyzing company profitability or the management effectiveness given the capital invested by the shareholders. ROE shows how efficiently a company utilizes investments to generate income.

Santhera Pharmaceuticals

Return On Equity

 = 

Net Income

Total Equity

 = 
-2.88
For most industries, Return on Equity between 10% and 30% are considered desirable to provide dividends to owners and have funds for the future growth of the company. Investors should be very careful using ROE as the only efficiency indicator because ROE can be high if a company is heavily leveraged.
Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.

Santhera Pharmaceuticals

Net Income

 = 

(Rev + Gain)

-

(Exp + Loss)

 = 
(41.97 M)
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.

Santhera Net Income Comparison

Santhera Pharmaceuticals is currently under evaluation in net income category among its peers.

Santhera Pharmaceuticals Profitability Projections

The most important aspect of a successful company is its ability to generate a profit. For investors in Santhera Pharmaceuticals, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Santhera Pharmaceuticals will eventually generate negative long term returns. The profitability progress is the general direction of Santhera Pharmaceuticals' change in net profit over the period of time. It can combine multiple indicators of Santhera Pharmaceuticals, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Last ReportedProjected for Next Year
Accumulated Other Comprehensive Income-3.8 M-4 M
Operating Income-38.4 M-40.3 M
Income Before Tax-37.5 M-39.4 M
Total Other Income Expense Net-7.5 M-7.1 M
Net Loss-37.8 M-39.7 M
Income Tax Expense358.8 K376.7 K
Net Loss-37.8 M-39.7 M
Net Loss-37.8 M-39.7 M
Net Interest Income-7 M-7.4 M
Interest Income1.1 MM
Change To Netincome14.6 M15.3 M
Net Loss(3.32)(3.49)
Income Quality 0.76  0.80 
Net Income Per E B T 0.91  0.76 

Santhera Profitability Driver Comparison

Profitability drivers are factors that can directly affect your investment outlook on Santhera Pharmaceuticals. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Santhera Pharmaceuticals position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Santhera Pharmaceuticals' important profitability drivers and their relationship over time.

Santhera Pharmaceuticals Earnings per Share Projection vs Actual

Use Santhera Pharmaceuticals in pair-trading

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Santhera Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Santhera Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.

Santhera Pharmaceuticals Pair Trading

Santhera Pharmaceuticals Holding Pair Trading Analysis

The ability to find closely correlated positions to Santhera Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Santhera Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Santhera Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Santhera Pharmaceuticals Holding to buy it.
The correlation of Santhera Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Santhera Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Santhera Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Santhera Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching

Use Investing Themes to Complement your Santhera Pharmaceuticals position

In addition to having Santhera Pharmaceuticals in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Outsourcing Thematic Idea Now

Outsourcing
Outsourcing Theme
Companies involved in providing outsourcing and staffing services to business across different domains. The Outsourcing theme has 32 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Outsourcing Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Santhera Stock Analysis

When running Santhera Pharmaceuticals' price analysis, check to measure Santhera Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Santhera Pharmaceuticals is operating at the current time. Most of Santhera Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Santhera Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Santhera Pharmaceuticals' price. Additionally, you may evaluate how the addition of Santhera Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.